Document Detail


Comparison of the relative efficacy and safety of low molecular weight heparin and unfractionated heparin for the treatment of venous thrombosis.
MedLine Citation:
PMID:  8979124     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
LMWH has been compared with unfractionated heparin in the treatment of venous thrombosis. The results of a pooled analysis studies of hospitalized patients showed a significant reduction of thrombus size, p < 0.001 and in the incidence of recurrent venous thromboembolism, p < 0.001 and of major bleeding p < 0.005 in patients treated with LMWH. The pooled mortality rate at long term follow-up was also found to be lower in LMWH group. Two large randomized trials have been completed in which LMWH was administered subcutaneously on an outpatient basis and compared with the standard approach of unfractionated heparin administered by continuous intravenous infusion in hospital. In both studies the efficacy, safety and mortality in the LMWH and heparin groups were similar.
Authors:
J Hirsh
Related Documents :
19260134 - Analysis of thrombosis on postoperative day 5 or later after microvascular reconstructi...
15597574 - Emerging options in the treatment of venous thromboembolism.
1422754 - Thromboembolic prophylaxis in total hip replacement: a comparison between the low molec...
18461274 - Disease-specific screening for deep venous thrombosis and pulmonary thromboembolism usi...
1612364 - Metallic self-expanding stent application in the upper gastrointestinal tract: caveats ...
17948074 - Oral ascorbic acid in combination with beta-blockers is more effective than beta-blocke...
Publication Detail:
Type:  Comparative Study; Journal Article; Review    
Journal Detail:
Title:  Haemostasis     Volume:  26 Suppl 4     ISSN:  0301-0147     ISO Abbreviation:  Haemostasis     Publication Date:  1996 Oct 
Date Detail:
Created Date:  1997-04-29     Completed Date:  1997-04-29     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0371574     Medline TA:  Haemostasis     Country:  SWITZERLAND    
Other Details:
Languages:  eng     Pagination:  189-98     Citation Subset:  IM    
Affiliation:
Hamilton Civic Hospitals Research Centre, Henderson General Division, Hamilton, ON, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Anticoagulants / therapeutic use*
Double-Blind Method
Enoxaparin / administration & dosage,  adverse effects,  therapeutic use
Fibrinolytic Agents / therapeutic use*
Hemorrhage / chemically induced,  epidemiology
Heparin / administration & dosage,  adverse effects,  therapeutic use*
Heparin, Low-Molecular-Weight / administration & dosage,  adverse effects,  therapeutic use*
Humans
Incidence
Infusions, Intravenous
Injections, Subcutaneous
Nadroparin / administration & dosage,  adverse effects,  therapeutic use
Partial Thromboplastin Time
Randomized Controlled Trials as Topic
Recurrence
Safety
Thromboembolism / epidemiology,  prevention & control*
Thrombolytic Therapy*
Thrombophlebitis / drug therapy*,  mortality
Warfarin / therapeutic use
Chemical
Reg. No./Substance:
0/Anticoagulants; 0/Enoxaparin; 0/Fibrinolytic Agents; 0/Heparin, Low-Molecular-Weight; 0/Nadroparin; 81-81-2/Warfarin; 9005-49-6/Heparin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effect of buflomedil on the neutrophil-endothelial cell interaction under inflammatory and hypoxia c...
Next Document:  Adhesive proteins at endothelial cell-to-cell junctions and leukocyte extravasation.